Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease

Thrombosis and Haemostasis

Volumn 101, Issue 6, 2009, Pages 1070-1077

  Zhou, Zhou ^a   Han, Hyojeong ^a   Cruz, Miguel A ^a   López, José A ^b   Dong, Jing Fei ^a   Guchhait, Prasenjit ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Thrombosis Research Section   (United States)

Author keywords

ADAMTS 13 activity; Extracellular haemoglobin; Sickle cell disease; Von Willebrand factor

Indexed keywords

ANTIBODY; HEMOGLOBIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BLOCKING ANTIBODY; HEMOGLOBIN A; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SICKLE CELL ANEMIA; CEREBROVASCULAR ACCIDENT; ENZYME ACTIVE SITE; ENZYME REPRESSION; ENZYME SPECIFICITY; ENZYMOLOGY; HYDROLYSIS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; THROMBOEMBOLISM;

ADAM PROTEINS; ANEMIA, SICKLE CELL; ANTIBODIES, BLOCKING; CATALYTIC DOMAIN; ENDOTHELIAL CELLS; ENZYME REPRESSION; HEMOGLOBIN A; HUMANS; HYDROLYSIS; PROTEIN BINDING; STROKE; SUBSTRATE SPECIFICITY; THROMBOEMBOLISM; VON WILLEBRAND FACTOR;

EID: 67049172151     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0677     Document Type: Article

References (26)

1. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease Nat Med 2002; 8: 1383-1389.
2. Savitsky JP, Doczi J, Black J, et al. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 1978; 23: 73-80. (Pubitemid 8290413)
3. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895. (Pubitemid 38252536)
4. Olsen SB, Tang DB, Jackson MR, et al. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation 1996; 93: 327-332. (Pubitemid 26031492)
5. Schnog JJ, Hovinga JA, Krieg S, et al. ADAMTS13 activity in sickle cell disease. Am J Hematol 2006; 81: 492-498.
6. Krishnan S, Siegel J, Pullen G, Jr., et al. Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res 2008; 122: 455-458.
7. Roberts DD, Rao CN, Liotta LA, et al. Comparison of the specificities of laminin, thrombospondin, and von Willebrand factor for binding to sulfated glycolipids. J Biol Chem 1986; 261: 6872-6877. (Pubitemid 17219456)
8. Wick TM, Moake JL, Udden MM, et al. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest 1987; 80: 905-910. (Pubitemid 18003966)
9. Kaul DK, Nagel RL, Chen D, et al. Sickle erythrocyte- endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 1993; 81: 2429-2438. (Pubitemid 23127081)
10. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra large von Willebrand factor multimers under flow. Blood 2004; 104: 100-106. (Pubitemid 38879844)
11. Studt JD, Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542-544. (Pubitemid 40070733)
12. Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. J Am Med Assoc 2005; 293: 1653-1662. (Pubitemid 40471796)
13. Cruz MA, Whitelock J, Dong JF. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. Thromb Haemost 2003; 90: 1204-1209. (Pubitemid 38004445)
14. Whitelock JL, Nolasco L, Bernardo A, et al. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2004; 2: 485-491. (Pubitemid 40185662)
15. Tao Z, Peng Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106: 4139-4145. (Pubitemid 41775919)
16. Choi H, Aboulfatova K, Pownall HJ, et al. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem 2007; 282: 35604-35611. (Pubitemid 350277098)
17. Li Y, Choi H, Zhou Z, et al. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost 2008; 6: 1135-1143. (Pubitemid 351859123)
18. Wick TM, Moake JL, Udden MM, et al. Unusually large von Willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells. Am J Hematol 1993; 42: 284-292. (Pubitemid 23079882)
19. Sadrzadeh SM, Graf E, Panter SS, et al. Hemoglobin. A biologic fenton reagent. J Biol Chem 1985; 259: 14354-14356. (Pubitemid 15222248)
20. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234. (Pubitemid 26152266)
21. Vischer UM, Jornot L, Wollheim CB, et al. Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood 1995; 85: 3164-3172.
22. Wagener FA, Eggert A, Boerman OC, et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 2001; 98: 1802-1811.
23. 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993; 82: 3548-3555.
24. Mohandas N, Evans E. Sickle erythrocyte adherence to vascular endothelium. Morphologic correlates and the requirement for divalent cations and collagenbinding plasma proteins. J Clin Invest 1985; 76: 1605-1612. (Pubitemid 16193582)
25. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435. (Pubitemid 13234018)
26. Hebbel RP, Boogaerts MA, Eaton JW, et al. Erythrocyte adherence to endothelium in sickle-cell anemia: A possible determinant of disease severity. N Engl J Med 1980; 302: 992-995. (Pubitemid 10125408)